Cannabis Business Times is pleased to announce that its seventh annual Best Cannabis Companies to Work For awards program, which identifies and recognizes the best employers in the industry, is now accepting entries. The program is open to all cannabis businesses, including plant-touching operators and ancillary companies based in the U.S. or Canada.

“We launched the Best Cannabis Companies to Work For program in 2020 to put a spotlight on companies that have created positive workplaces,” said Noelle Skodzinski, Cannabis Business Times founder and editorial director. “The industry’s rapid growth as legalization spread created great opportunity but also challenges for employers. Job-hopping was and still is very common, as employees search for better places to work.”

“Retail, cultivation, and manufacturing experience the highest turnover rates,” according to the “2023 Vangst Salary Guide.”

In cannabis retail, turnover rates reached 59% in the U.S. and 60% in Canada­ during a 12-month period between 2021 and 2022, according to Headset data.

“Amid high turnover, companies continue to struggle to retain top talent, and they spend a lot of time and money trying to recruit and train new employees,” Skodzinski said. “The Best Cannabis Companies to Work For program was designed to call out top employers and their best practices, giving those companies the recognition they deserve, and helping others learn how to create supportive, engaging work environments, while helping industry employees find great places to work.” Root & Bloom ranked No. 1 in the 2024 Best Cannabis Companies To Work For – Cultivation list. CEO Tom Regan, left, and VP of Cultivation William Windham, photographed at the Root & Bloom cultivation facility in January 2024. Photo by Cynthia August

And the need for creating engaging work environments has only increased for all businesses. In 2024, the percentage of employees who are engaged at their jobs dropped to a 10-year low, according to a Gallup report.

Employee engagement is important beyond being a way to reduce turnover, however. Highly engaged employees achieve greater productivity and profitability, and higher customer loyalty/engagement, among other things, per Gallup’s Q12 Employee Engagement Survey. They also achieve less employee theft, and fewer quality defects, according to the survey.

In addition to entering to gain recognition for being great places to work, all companies that enter, whether they rank as a ‘Best Company’ or not, also have the ability to purchase from the Workforce Research Group an Employee Feedback Data Dashboard, which provides aggregated employee feedback and benchmarks to help the companies identify ways to improve their work environments and better engage employees.PayRio ranked in the No. 1 spot on the Best Cannabis Companies to Work For – 2025 list. Pictured are team members at Hall of Flowers in Santa Rosa, Calif.Photo courtesy PayRio

Cannabis businesses can enter to be a Best Cannabis Company here. The registration deadline is Oct. 3.

About Cannabis Business Times’ Best Cannabis Companies to Work For Rankings
The Best Cannabis Companies to Work For is a research-driven program conducted by Cannabis Business Times in partnership with independent research firm Workforce Research Group. Entering companies must complete an employer questionnaire about their workplace benefits and practices, and a certain percentage of their employees must complete an anonymous employee questionnaire.

One of the things that makes the Best Cannabis Companies to Work For rankings unique is the methodology, which heavily weighs (80% of a company’s total score) the employee feedback.

Ranking companies are featured by Cannabis Business Times and are able to display the program logo on their websites and in recruiting and marketing materials.

For more information, visit the Best Cannabis Companies to Work For — 2026 website.  

View ranking companies from Cannabis Business Times‘ Best Cannabis Companies to Work For —  2025 here.

Texas Gov. Greg Abbott (R) has signed into law a bill to create a state-backed research consortium to conduct clinical trials on ibogaine as a possible treatment for substance use disorders and other mental health conditions. The ultimate goal of the project is to develop the psychedelic into a prescription drug with U.S. Food and Drug Administration (FDA) approval, with the state retaining a portion of the profit.

“Texas is now leading the way in the United States for the evaluation of ibogaine as a potential medication that can help improve the lives of so many Americans,” the governor said at a signing event on Wednesday. He called the psychedelic “a therapy that has shown great promise in treating” conditions such as depression, PTSD and opioid use disorder.

“I’m about to sign a law that will lead to an FDA-approved drug development clinical trial that will seek approval of ibogaine as a medication for the treatment of opioid use disorder and other behavioral health conditions, especially those suffered by our veterans,” he added. “Texas will invest $50 million to support this research, and these funds can be matched by grants and private investments.”

Under the new law, approved by the state legislature earlier this month, Texas will retain a commercial interest in “all intellectual property that may be generated over the course of the drug development clinical trials,” the legislation says, with an aim of making Texas a hub for “ibogaine-related biomedical research, development, treatment, manufacturing, and distribution.”

A quarter of revenue taken in by the state from any resulting intellectual property would fund veterans programs.

House Speaker Dustin Burroughs (R) said at the event that while he knew little about ibogaine before the session began, lawmakers “heard story after story” from people who said the therapy had improved their lives.

“It made an impact,” he said, “and slowly, as session went on, the members of the Texas House, members of the Senate, began to agree that this was worth the next step. It was worth investing in and…seeing if we could do something to bring this to more people.”

Bill sponsor Sen. Tan Parker (R) said the new law “is about the opportunity to restore the lives of so many veterans that have put their lives on the line for all of us.”

“We’re incredibly excited to take this step. There’s nothing more important than protecting our veterans and our public at large,” Parker said. “This will have benefits for everyone if the clinical trial is successful, as we believe it will be.”

As for what happens next, he said that “within 60 days,” the state is expected to start receiving proposals from institutions and organizations to be part of the consortium.

“The money that Texas is investing will only be put in based on a match, based on private funds being contributed by people that have great expertise,” he continued. “So we’re looking forward to that consortium…coming forward, and again, we’ll be receiving those proposals 60 days from now.”

Along with the legislation’s goal of winning FDA approval as a clinical treatment, the bill says it also seeks “a breakthrough therapy designation for ibogaine”—a designation FDA gives to emerging treatment options that haven’t yet secured agency approval to treat a particular condition.

After the House and Senate passed separate versions of the measure, it was amended by a bicameral conference committee. The compromise legislation passed the Senate on a 26–5 vote and the House 134–4.

Rather than create a state grant program to support research on the psychedelic, as previous forms of the bill would have done, the compromise version of the bill establishes a “consortium”—including an institution of higher education, a hospital and a drug developer—to develop and test ibogaine drugs in an effort to secure FDA approval.

The educational institution would serve as the consortium’s leader, representing the group to the state Health and Human Services  Commission (HHSC) and handling administrative functions. It would further be responsible for submitting “a proposal and request for funding on behalf of the consortium for purposes of conducting ibogaine drug development clinical trials in accordance with this subchapter.”

—
Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
—

The program is set to be funded through a $50 million appropriation from the state general fund, which would go to HHSC for disbursement to cover the drug development trials, according to a conference committee report for SB 1, a massive state budget bill. Private gifts, grants and donations would also be accepted.

“Initially, no state funding was appropriated for the initiative,” sponsor Parker explained to colleagues earlier this month. “However, that has now changed.”

A fiscal note on the final conference committee bill says HHSC will need to appropriate money “to fund the consortium’s clinical trials, but the cost of such funding is unknown at this time.”

As for revenue stemming from intellectual property resulting from the research and new drug development, the analysis says the amount “is indeterminate and would be dependent on the drug development trials.”

Revenue from the project would flow into Texas’s general fund, and from there 25 percent would be earmarked “only to programs that assist veterans in this state.”

Rep. Greg Bonnen (R) said on the House floor before the vote on the proposal that said “the state will have negotiated for royalties at a minimum of 20 percent.”

Reformers have cheered the legislation. Bryan Hubbard, executive director of the American Ibogaine Initiative and an architect of the bill, said of the final version that “I have to give the legislature an A across the board.”

“I think that it can stand up as a national model for other states that wish to replicate it in some form or fashion,” he said in an interview with Marijuana Moment after the bill’s passage in the legislature, thanking in particular sponsors Parker and Rep. Cody Harris (R) as well as House Speaker Burroughs and Lt. Gov. Dan Patrick (R), who presides over the Senate.

“Without the courage and vision of those four individuals, none of this would have happened,” Hubbard said, “and I am forever grateful to Texas leadership for making this, in my estimation, one of the greatest single achievements in the history of the of the American psychedelic movement.”

Hubbard said at the time that he believes the state having a vested interest in intellectual property produced by the research will ensure Texans see “a perpetual return on their investment.”

“Most Americans, I believe, have had enough of public dollars going into the pockets of private corporations with no return on investment for the taxpayer,” he said. “With the way in which Texas has set this project up, Texas taxpayers are going to be fully vested partners in this endeavor, and the people of Texas will see—if we are successful—perpetual return on their investment that will hopefully be used to assure universal treatment access through a top-notch, ibogaine-based treatment and recovery system as time and circumstances evolve.”

An earlier analysis of the legislation said that opioid use disorder (OUD) “continues to be one of the most insidious threats to public health of our time, devastating individuals, families, and communities across Texas and our nation,” and “current treatment options are often unsuccessful in treating OUD and lives are lost as a result.”

Hubbard noted that the new Texas plan is similar to an ibogaine research proposal a few years ago in Kentucky that he also helped design. That bill would have distributed at least $42 million in funding for research into ibogaine’s potential to treat opioid addiction.

The effort fell through in late 2023 after the state’s new attorney general replaced Hubbard, who was then serving as chair of the Kentucky Opioid Commission, with a former Drug Enforcement Administration (DEA) official.

Last year advocates tried to enact a similar plan in Ohio.

“The legislation that you see is the Kentucky plan as implemented by the state of Texas,” Hubbard said. In terms of the consortium, the way that they have set this up is to create a cooperation framework on the front end that I had always envisioned occurring on the back end.”

“When this program was designed for Kentucky, I had in mind that we would essentially send out an RFP [request for proposals] for a drug developer, send out an RFP for a trial site, and to pick the best. And to pair the drug developer with trial science on the back end,” he explained.

“In the Texas framework, this is a cooperative partnership that will have to be built on the front end by those who want to be able to pursue this opportunity,” Hubbard continued. “There is a role for both universities and private hospitals, which is important because they each have significant things to contribute.”

HHSC will retain control over the consortium, he said, “and the reason that that legal authority needs to be there is because you want the absolute best drug developer and you want the absolute best aggregation of trial sites within Texas, who can make sure that these trials are done safely, efficiently and effectively.”

Meanwhile in Texas, a new statewide poll finds that Republican primary voters oppose a separate proposal to ban hemp products containing THC that lawmakers recent sent to the governor’s desk.

While Abbott has declined to say how he’ll act on SB 3—which advocates and stakeholders say would decimate the state’s hemp industry—the policy change evidently isn’t being embraced by voters, including a plurality of Republicans (47 percent) who voiced opposition, said the survey, from Ragnar Research Partners and commissioned the Texas Hemp Business Council (THBC).

Military veterans advocates, including Texas Veterans of Foreign Wars, have called on the governor to veto the hemp ban, saying it “would cause irreversible harm to communities across the state.”

Farmers have also said the prohibition would devastate a key sector of the state’s agriculture industry.

Last month, the Texas House also passed a pair of bills designed to ensure speedy access to psychedelic-assisted therapy in the event of FDA approval, but they did not clear the Senate by the end of the session.

More recently, lawmakers passed a bill to significantly expand the state’s medical marijuana program, sending it to the governor.

The measure would expand the state’s list of medical cannabis qualifying conditions to include chronic pain, traumatic brain injury (TBI), Crohn’s disease and other inflammatory bowel diseases, while also allowing end-of-life patients in palliative or hospice care to use marijuana.

Separately, a House committee approved a Senate-passed bill last month that would prohibit cities from putting any citizen initiative on local ballots that would decriminalize marijuana or other controlled substances—as several localities have already done despite lawsuits from the state attorney general.

Under the proposal, state law would be amended to say that local entities “may not place an item on a ballot, including a municipal charter or charter amendment, that would provide that the local entity will not fully enforce” state drug laws.

While several courts have previously upheld local cannabis decriminalization laws, an appellate court comprised of three conservative justices appointed by the governor has recently pushed back against two of those rulings, siding with the state in its legal challenge to the marijuana policy in Austin and San Marcos.

Despite the ongoing litigation and advancement of the House and Senate bills, Texas activists have their targets set on yet another city, Kyle, where they hope put an initiative before voters to enact local marijuana reform at the ballot this coming November.

A recent poll found that four in five Texas voters want to see marijuana legalized in some form, and most also want to see regulations around cannabis relaxed.

GOP-Led Congressional Panel Demands Investigation On Biden’s Marijuana Rescheduling Process, Citing ‘Deviations’ And ‘Mental Health Hazards’

Photo courtesy of Flickr/Scamperdale.

The first big holiday party weekend of the summer and beer didn’t make the biggest splash…did a green plant figure in to the issue?

Beer is at the heart of Memorial Day celebrations—a crisp, refreshing companion to beach days, backyard BBQs, and gatherings with friends and family. It is in the top drivers to alcohol sales. But this year, a flat holiday weekend occurred amid long-running concerns over beer’s decline. Is cannabis part of Memorial Day’s beer sales drop? Over the 2025 Memorial Day weekend, beer sales underwhelmed expectations, according to a Goldman Sachs survey of roughly 50 distributors covering nearly half of U.S. alcohol retailers.

RELATED: How Marijuana Can Heighten Intimacy With Your Partner

Among major brands, Heineken showed the sharpest decline, with 66% of distributors reporting lower sales than last year. Bud Light, Corona Extra, and Miller Lite also posted year-over-year drops, while select brands like ABI, Pacifico, and Twisted Tea bucked the trend with modest gains. Distributors largely pointed to persistent inflation, tariff worries, shifting consumer taste toward spirits or more “sophisticated” drinks, and reduced alcohol consumption among Millennials and Gen Z—which aligns with Gallup data showing only 62% of 18–34‑year-olds reported drinking alcohol from 2021–2023, compared to 72% two decades ago.

In Canada, where adult-use cannabis has been legal since 2018, beer sales volumes shrank sharply: an immediate drop of 96 hectolitres per 100,000 population, with an ongoing monthly fall worth 136 hectolitres—a trend linked with increased cannabis spending . Statistics Canada data for 2023/24 showed beer volume fell 4.5%, the steepest yearly decline since tracking began in 1949. A specific Nova Scotia study found a 2.2% drop right after legalization, with sustained lower sales afterward.

A Bernstein‑cited Numerator survey indicated 36% of cannabis‑using drinkers now drink less alcohol, and almost half say they’ve replaced some alcohol with cannabis . Moreover, cannabis users have shown a stronger preference to forgo beer over other alcohol types.

Jon Taffer, host of Bar Rescue, asserts no doubt exists that cannabis‑infused beverages are altering drinking habits in the U.S.: “It’s no question cannabis is affecting the spirits industry,” with CBD drinks projected to grow from $5.3 billion in 2021 to $16 billion by 2026.

RELATED: Being A Couch Potato Changes Your Personality

But cannabis isn’t the sole factor. Rising health consciousness—including trends like “Dry January”—and new warnings linking alcohol to cancer are pushing consumers toward lower-alcohol or alcohol-free options. Meanwhile, economic pressures (inflation, tariff concerns, tight household budgets) persist. Adding strategic shifts from younger generations and innovations in non-alcoholic drinks, the drinking landscape is clearly evolving.

For beer brands, the path forward lies in diversification—expanding non‑alcoholic lines and tapping into cannabis‑adjacent markets. Heineken and Constellation Brands have already made early moves, while craft breweries explore cannabis-infused variants. Meanwhile, cannabis companies like Tilray are snapping up craft breweries to leverage distribution networks and position for future crossover products.

Cannabis isn’t the only culprit—but growing evidence suggests a meaningful portion of consumers are replacing beers with cannabis products or cannabis-infused drinks. As both industries innovate, beer brands that adapt—by offering alcohol-free options or partnering with cannabis—will have a better chance at regaining relevance in a changing marketplace.